RESULTS OF TREATING LUMINAL A BREAST CANCER WITHOUT REGIONAL OR DISTANT METASTASES
Objective. To determine the most effective type of treating (hormonotherapy, chemohormonotherapy) operable patients with luminal A subtype of breast cancer with undamaged regional lymphatic collector in terms of five-year overall, disease-free and cancer-specific survival.
Material and methods. The cancer registry data, the outpatient records, case histories, and tumor material of 168 patients suffering from resectable luminal A breast cancer who had underwent radical treatment in the N. N. Alexandrov National Cancer Centre of Belarus in 2006—2009 were studied.
Results. It was established that for the luminal A subtype of breast cancer and for prevalence of the process within
T1-4N0M0, chemohormonotherapy had no advantages over hormonotherapy: the overall survival was 93.2±3.3% and 89.0±2.9% (p=0.706); the disease-free survival was 84.6±4.7% and 100.0±0.0% (p=0.001); the cancer-specific survival was 96.5±2.4% and 99.0±1.0% (p=0.013), respectively.
Conclusion. The adjuvant hormonotherapy is the most effective therapeutic method for the luminal A breast cancer (T1-4N0M0).